LANSOPRAZOLE by Novartis is compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (h , k )-atpase enzyme system at the secretory surface of the gastric parietal cell. Approved for symptom relief of active duodenal ulcer [ see clinical studies (, symptom relief of active benign gastric ulcer [ see clinical studies (, inclu. First approved in 2010.
Drug data last refreshed 21h ago
compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H , K )-ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the parietal cell, lansoprazole…
Worked on LANSOPRAZOLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)